Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haloperidol: therapeutic window in schizophrenia

D J Palao1, A Arauxo, M Brunet

  • 1Department of Psychiatry, Hospital Clínic i Provincial, Barcelona, Spain.

Journal of Clinical Psychopharmacology
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum: The Hubbard dimer: a density functional case study of a many-body problem (2015<i>J. Phys.: Condens. Matter</i><b>27</b>393001).

Journal of physics. Condensed matter : an Institute of Physics journal·2026
Same author

A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250).

ESMO open·2025
Same author

Resilient outcomes in people with a history of mental disorder during the COVID-19 pandemic: an international 2-years longitudinal prospective study.

Social psychiatry and psychiatric epidemiology·2025
Same author

The role of childhood maltreatment and mental health disorders on suicidal behaviour in adolescents.

Child abuse & neglect·2024
Same author

Genetic architecture of oral glucose-stimulated insulin release provides biological insights into type 2 diabetes aetiology.

Nature metabolism·2024
Same author

Metabolic and productive adaptive response of beef cows to successive short-nutritional challenges.

Research in veterinary science·2024

This study found an optimal therapeutic window for haloperidol plasma levels in schizophrenic patients. Maintaining haloperidol within 5.5 to 14.4 ng/ml improves clinical response and reduces negative symptoms.

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Neuroscience

Background:

  • Haloperidol is a typical antipsychotic used for schizophrenia.
  • Determining optimal therapeutic plasma levels is crucial for effective treatment.
  • Previous research suggests a dose-response relationship, but a defined therapeutic window is needed.

Purpose of the Study:

  • To investigate the relationship between haloperidol plasma concentrations and clinical response in schizophrenic patients.
  • To identify a therapeutic window for haloperidol to optimize treatment outcomes.

Main Methods:

  • Twenty-two inpatients with schizophrenia received fixed oral doses of haloperidol (10, 20, or 30 mg) for 3 weeks.
  • Plasma haloperidol levels were measured.
  • Clinical response was assessed using the Brief Psychiatric Rating Scale.

Related Experiment Videos

  • A nonlinear regression model was employed to analyze the data.

    • Main Results:

    • A curvilinear relationship was observed between haloperidol plasma levels and clinical response (pseudo-R2 = 0.85, p < 0.001).
    • Three drug level ranges were identified: low (< 5.5 ng/ml), optimal (5.5–14.4 ng/ml), and high/toxic (> 14.4 ng/ml).
    • Higher haloperidol levels were associated with less improvement or worsening of negative symptoms and a trend towards more extrapyramidal symptoms.

    Conclusions:

    • The study supports the existence of a therapeutic window for haloperidol in schizophrenia treatment.
    • Achieving haloperidol plasma levels within the optimal range (5.5–14.4 ng/ml) increases the probability of global clinical improvement.
    • This finding has significant implications for clinical practice in managing schizophrenia exacerbations.